Quick Summary:
The growing Global Migraine Drugs Market estimated at $2.8 Billion in 2022 is forecasted to almost triple in size, reaching $9.2 Billion by 2030. For executives striving to capitalize on this surge, the in-depth insights offered by this comprehensive market research report can serve as a crucial guide. The report not only helps identify key growth drivers and promising regions for investment but also offers analysis of notable segments like Acute and Preventive Treatment sciences, enabling strategic decision-making based on data.
While the U.S market remains robust, our report shines light on rapidly growing markets like China, projected to grow at an impressive CAGR of 21.8% over the next eight years. Furthermore, the report presents detailed profiles of 59 top-tier competitors, offering insights on their strategies, market share, and geographic presence. Invaluable insights like these empower executives to devise winning strategies, optimize their market position, and drive future growth. Unleash the power of informed decisions with our extensive Migraine Drugs Market research report, which includes one-year complimentary updates and access to our digital archives.
Global Migraine Drugs Market to Reach $9.2 Billion by 2030
The global market for Migraine Drugs estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of US$9.2 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2022-2030. Acute Treatment, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$7.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Preventive Treatment segment is readjusted to a revised 14.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $753.3 Million, While China is Forecast to Grow at 21.8% CAGR
The Migraine Drugs market in the U.S. is estimated at US$753.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 21.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 14% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.Select Competitors (Total 59 Featured) -
- Allergan PLC
- Amgen, Inc.
- Biohaven Pharmaceutical Holding Company Ltd.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Migraine Drugs?
What is the growth rate of the Global Market for Migraine Drugs?
What is the forecasted size of the Global Market for Migraine Drugs?
Who are the key companies in the Global Market for Migraine Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2.8 Billion |
| Forecasted Market Value ( USD | $ 9.2 Billion |
| Compound Annual Growth Rate | 16.0% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Allergan PLC
- Amgen, Inc.
- Biohaven Pharmaceutical Holding Company Ltd.
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
